Helsinn Healthcare SA
helsinn.comTotal trials
32
Active
1
Phase 3
13
Total enrollment
8,495
Read this sponsor's pipeline like an analyst.
Generate a written report: strategic focus, priority programs, pipeline shape, recent terminations and momentum, and the trials worth watching in the next 12 months.
~15-30 sec · cached for 24h
Pipeline matrix
Showing 3 of 3 active programs · click any cell for trials
| Intervention | Early Phase 1 | Phase 1 | Phase 2 | Phase 3 | Phase 4 | N/A | Total |
|---|---|---|---|---|---|---|---|
| IV NEPA | — | — | — | — | — | 1 | |
| Reference Treatment: IV ondansetron | — | — | — | — | — | 1 | |
| Reference Treatment: IV fosaprepitant | — | — | — | — | — | 1 |
Next readouts
- 2027-10
Top conditions
- Chemotherapy-Induced Nausea and Vomiting6
- Healthy Volunteers3
- Myelodysplastic Syndrome2
- Chemotherapy-induced Nausea and Vomiting2
- Cachexia; Cancer2
- Non Small Cell Lung Cancer2
- Postoperative Nausea and Vomiting2
- Non-smokers2
Frequently asked questions about Helsinn Healthcare SA
- How many clinical trials does Helsinn Healthcare SA have on ClinicalTrials.gov?
- Helsinn Healthcare SA is listed as the lead sponsor on 32 clinical trials in ClinicalTrials.gov, 1 of which are currently active (recruiting, enrolling, or ongoing).
- How many of Helsinn Healthcare SA's trials are in Phase 3?
- 13 of Helsinn Healthcare SA's trials are in Phase 3, spread across 3 active drug programs.
- What therapeutic areas does Helsinn Healthcare SA focus on?
- Helsinn Healthcare SA's most-studied conditions on ClinicalTrials.gov are Chemotherapy-Induced Nausea and Vomiting, Healthy Volunteers, Myelodysplastic Syndrome, Chemotherapy-induced Nausea and Vomiting, Cachexia; Cancer.
- When are Helsinn Healthcare SA's next clinical trial readouts?
- Helsinn Healthcare SA has 1 upcoming primary-completion readout tracked here; the soonest is “Study With IV NEPA (Fosnetupitant/Palonosetron) for the Prevention of Chemotherapy-induced Nausea and Vomiting in Paediatric Cancer Patients Undergoing Highly Emetogenic Chemotherapy (HEC)”, expected around 2027-10.